PL2834237T3 - Związki heterocyklilowe jako inhibitory mek - Google Patents

Związki heterocyklilowe jako inhibitory mek

Info

Publication number: PL2834237T3
Authority: PL; Poland
Prior art keywords: mek inhibitors; heterocyclyl compounds; heterocyclyl; compounds; mek
Prior art date: 2012-03-14

Application number

PL13712929T

Other languages

English (en)

Inventor

Bhavesh Dave

Rakesh Kumar Banerjee

Samiron Phukan

Abhijit Datta Khoje

Rajkumar HANGARGE

Jitendra Sambhaji Jadhav

Venkata P. Palle

Rajender Kumar Kamboj

Original Assignee

Lupin Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-14

Filing date

2013-03-11

Publication date

2018-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2834237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-11 Application filed by Lupin Limited filed Critical Lupin Limited

2018-11-30 Publication of PL2834237T3 publication Critical patent/PL2834237T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)

PL13712929T 2012-03-14 2013-03-11 Związki heterocyklilowe jako inhibitory mek PL2834237T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN288KO2012		2012-03-14
EP13712929.2A EP2834237B1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors
PCT/IB2013/051908 WO2013136249A1 (en)	2012-03-14	2013-03-11	Heterocyclyl compounds as mek inhibitors

Publications (1)

Publication Number	Publication Date
PL2834237T3 true PL2834237T3 (pl)	2018-11-30

Family

ID=47997632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13712929T PL2834237T3 (pl)	2012-03-14	2013-03-11	Związki heterocyklilowe jako inhibitory mek

Country Status (35)

Country	Link
US (5)	US9428499B2 (pl)
EP (2)	EP2834236B1 (pl)
JP (3)	JP6093384B2 (pl)
KR (4)	KR102240101B1 (pl)
CN (4)	CN104271577A (pl)
AP (2)	AP3834A (pl)
AU (4)	AU2013234014B2 (pl)
BR (1)	BR112014022713B1 (pl)
CA (2)	CA2865167C (pl)
CL (2)	CL2014002412A1 (pl)
CO (2)	CO7170131A2 (pl)
CR (2)	CR20140463A (pl)
CU (2)	CU24272B1 (pl)
DK (2)	DK2834237T3 (pl)
DO (2)	DOP2014000204A (pl)
EA (2)	EA028232B1 (pl)
ES (2)	ES2684517T3 (pl)
GE (2)	GEP201706774B (pl)
GT (2)	GT201400196A (pl)
IL (2)	IL234559A (pl)
IN (2)	IN2014MN01754A (pl)
MA (2)	MA37405A1 (pl)
MX (3)	MX355474B (pl)
MY (2)	MY174188A (pl)
NI (2)	NI201400107A (pl)
NZ (2)	NZ629442A (pl)
PE (2)	PE20141974A1 (pl)
PH (2)	PH12014502041A1 (pl)
PL (1)	PL2834237T3 (pl)
SG (2)	SG11201405007QA (pl)
TN (2)	TN2014000356A1 (pl)
TR (1)	TR201811976T4 (pl)
UA (2)	UA114907C2 (pl)
WO (2)	WO2013136254A1 (pl)
ZA (1)	ZA201406186B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TR201811976T4 (tr)	2012-03-14	2018-09-21	Lupin Ltd	Mek inhibitörleri olarak heterosiklil bileşikleri.
SI2861595T1 (sl)	2012-06-13	2017-04-26	Incyte Holdings Corporation	Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
ES2657451T3 (es)	2013-04-19	2018-03-05	Incyte Holdings Corporation	Heterocíclicos bicíclicos como inhibidores del FGFR
RU2667892C2 (ru) *	2013-10-25	2018-09-25	Шанхай Хэнжуй Фармасьютикал Ко., Лтд.	Производные пиридилкетона, способ их получения и их фармацевтическое применение
WO2016009306A1 (en) *	2014-07-15	2016-01-21	Lupin Limited	Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) *	2014-09-04	2016-03-10	Lupin Limited	Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en)	2015-02-20	2024-02-27	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
CN110167928A (zh)	2016-12-22	2019-08-23	勃林格殷格翰国际有限公司	作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10829487B2 (en)	2017-12-21	2020-11-10	Boehringer Ingelheim International Gmbh	Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
KR20210018265A (ko)	2018-05-04	2021-02-17	인사이트 코포레이션	Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022537044A (ja)	2019-06-19	2022-08-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗がん併用療法
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
MX2022001328A (es) *	2019-07-30	2022-05-20	Edvince Ab	Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
EP3797899A1 (de)	2019-09-27	2021-03-31	Primetals Technologies Austria GmbH	Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP2023500906A (ja)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CR20220285A (es)	2019-12-04	2022-10-27	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CA3183656A1 (en) *	2020-06-02	2021-12-09	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
WO2022214594A1 (en)	2021-04-09	2022-10-13	Boehringer Ingelheim International Gmbh	Anticancer therapy
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4323066A1 (en) *	2021-04-16	2024-02-21	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
US12280055B2 (en)	2021-05-27	2025-04-22	Mirati Therapeutics, Inc.	Combination therapies
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CN119013272A (zh)	2021-12-01	2024-11-22	勃林格殷格翰国际有限公司	用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
TW202337431A (zh)	2021-12-01	2023-10-01	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20250145608A1 (en)	2021-12-01	2025-05-08	Boehringer Ingelheim Int'l GmbH Corp.	Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CN118613485A (zh)	2021-12-01	2024-09-06	勃林格殷格翰国际有限公司	用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
US20250129096A1 (en)	2021-12-01	2025-04-24	Boehringer Ingelheim Int'l GmbH Corp.	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114573582B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114605408B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) *	2022-03-30	2023-09-01	沈阳药科大学	5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
WO2023230205A1 (en)	2022-05-25	2023-11-30	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
JP2024047569A (ja) *	2022-09-26	2024-04-05	ファイザー・インク	Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
WO2024246099A1 (en)	2023-05-30	2024-12-05	Boehringer Ingelheim International Gmbh	Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
UA72612C2 (en) *	2000-07-06	2005-03-15		Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) *	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
GB0129099D0 (en)	2001-12-05	2002-01-23	Astrazeneca Ab	Chemical compounds
PL220952B1 (pl) *	2002-01-22	2016-01-29	Warner Lambert Co	2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
UA84175C2 (ru)	2003-11-19	2008-09-25	Аррей Байофарма Инк.	Гетероциклические ингибиторы мэк и их применение
EP1761528B1 (en) *	2004-06-11	2008-01-09	Japan Tobacco, Inc.	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
CN102458580A (zh)	2009-04-21	2012-05-16	诺瓦提斯公司	作为mek抑制剂的杂环化合物
TR201811976T4 (tr)	2012-03-14	2018-09-21	Lupin Ltd	Mek inhibitörleri olarak heterosiklil bileşikleri.

2013
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
2014
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040A1/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active

Also Published As

Publication number	Publication date
NI201400108A (es)	2014-11-28
DK2834236T3 (da)	2019-08-26
BR112014022713A2 (pl)	2017-06-20
KR102240101B1 (ko)	2021-04-14
UA114906C2 (uk)	2017-08-28
EA029768B1 (ru)	2018-05-31
NI201400107A (es)	2014-11-26
PH12014502041B1 (en)	2014-11-24
NZ629442A (en)	2016-12-23
US9555035B2 (en)	2017-01-31
US9827247B2 (en)	2017-11-28
JP2018115215A (ja)	2018-07-26
ZA201406186B (en)	2016-06-29
KR20140138910A (ko)	2014-12-04
TR201811976T4 (tr)	2018-09-21
EP2834237A1 (en)	2015-02-11
EA028232B1 (ru)	2017-10-31
JP6630771B2 (ja)	2020-01-15
IN2014MN01755A (pl)	2015-07-03
EP2834236A1 (en)	2015-02-11
AU2013234014A1 (en)	2014-09-25
US9573944B2 (en)	2017-02-21
CA2865167C (en)	2019-08-06
ES2684517T3 (es)	2018-10-03
MA37400B1 (fr)	2019-11-29
CN107698585A (zh)	2018-02-16
CN108383836B (zh)	2021-11-12
PH12014502040B1 (en)	2014-11-24
DK2834237T3 (en)	2018-08-27
AP3834A (en)	2016-09-30
SG11201405007QA (en)	2014-10-30
MX355474B (es)	2018-04-16
CL2014002412A1 (es)	2015-03-06
IN2014MN01754A (pl)	2015-07-03
JP2015509975A (ja)	2015-04-02
CN108383836A (zh)	2018-08-10
UA114907C2 (uk)	2017-08-28
NZ629432A (en)	2017-01-27
JP6093384B2 (ja)	2017-03-08
BR112014022713B1 (pt)	2021-09-08
CA2865167A1 (en)	2013-09-19
KR102241111B1 (ko)	2021-04-15
CA2865164C (en)	2021-06-08
TN2014000357A1 (en)	2015-12-21
KR20190073597A (ko)	2019-06-26
HK1206020A1 (en)	2015-12-31
WO2013136254A1 (en)	2013-09-19
CA2865164A1 (en)	2013-09-19
PH12014502041A1 (en)	2014-11-24
CR20140464A (es)	2014-11-28
US9428499B2 (en)	2016-08-30
US20160331753A1 (en)	2016-11-17
JP2015514056A (ja)	2015-05-18
US20150133424A1 (en)	2015-05-14
GT201400196A (es)	2017-09-28
SG11201405006PA (en)	2014-10-30
AU2013234014B2 (en)	2017-02-02
AP2014008009A0 (en)	2014-10-31
CR20140463A (es)	2014-11-28
HK1202538A1 (en)	2015-10-02
AU2017200493B2 (en)	2018-03-29
CN104203947A (zh)	2014-12-10
EA201491671A1 (ru)	2014-12-30
US20170101408A1 (en)	2017-04-13
MY174188A (en)	2020-03-12
AU2013234009A1 (en)	2014-09-25
GEP201706671B (en)	2017-05-25
US20150299186A1 (en)	2015-10-22
CU20140109A7 (es)	2014-11-27
DOP2014000204A (es)	2015-02-15
ES2741896T3 (es)	2020-02-12
AU2018202568B2 (en)	2019-05-09
CU20140110A7 (es)	2014-11-27
AU2017200493A1 (en)	2017-02-16
CO7160029A2 (es)	2015-01-15
EA201491672A1 (ru)	2014-12-30
AU2018202568A1 (en)	2018-05-10
US9969731B2 (en)	2018-05-15
MX366426B (es)	2019-07-08
CU24335B1 (es)	2018-04-03
MA37400A1 (fr)	2016-05-31
US20170112840A1 (en)	2017-04-27
PH12014502040A1 (en)	2014-11-24
EP2834237B1 (en)	2018-06-06
PE20141973A1 (es)	2014-12-12
WO2013136249A1 (en)	2013-09-19
DOP2014000203A (es)	2015-02-15
MX355526B (es)	2018-04-20
IL234559A (en)	2017-06-29
GT201400195A (es)	2017-11-09
PE20141974A1 (es)	2014-12-12
CN104271577A (zh)	2015-01-07
KR20140138911A (ko)	2014-12-04
MX2014010928A (es)	2015-04-10
GEP201706774B (en)	2017-11-27
MY175950A (en)	2020-07-16
TN2014000356A1 (en)	2015-12-21
MA37405A1 (fr)	2016-03-31
EP2834236B1 (en)	2019-05-22
JP6431770B2 (ja)	2018-11-28
CO7170131A2 (es)	2015-01-28
AP3859A (en)	2016-10-31
KR20190100472A (ko)	2019-08-28
AP2014008008A0 (en)	2014-10-31
AU2013234009B2 (en)	2016-10-27
CL2014002411A1 (es)	2015-04-06
MX2014010925A (es)	2015-04-10
IL234560A (en)	2017-06-29
CU24272B1 (es)	2017-08-08

Publication	Publication Date	Title
AP3859A (en)	2016-10-31	Heterocyclyl compounds as MEK inhibitors
ZA201501009B (en)	2017-11-29	Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201407694B (en)	2015-05-27	Substituted pyrrolidine-2-carboxamides
IL235986A0 (en)	2015-02-01	Tetrahydropyrazolopyrimidine compounds
SMT201700596T1 (it)	2018-01-11	Composti inibitori
AP2014007810A0 (en)	2014-07-31	Imidazopyrrolidinone compounds
LT2920149T (lt)	2019-07-10	3-aminocikloalkilo junginiai, kaip ror-gama-t inhibitoriai, ir jų panaudojimas
SG11201404344XA (en)	2014-10-30	Substituted pyrrolidine-2-carboxamides
ZA201406225B (en)	2016-05-25	Thiadiazolidinediones as gsk-3 inhibitors
GB201202368D0 (en)	2012-03-28	Tracking method
GB201214842D0 (en)	2012-10-03	Content tracker
IL239153A0 (en)	2015-07-30	Substitute pyridopyrazine as an inhibitor
EP2934541A4 (en)	2016-08-03	NORIBOGAINE SUBSTITUTE
IL235919A0 (en)	2015-02-01	inhibitors of fbxo3
GB201211019D0 (en)	2012-08-01	Inhibitor compounds
EP2820568A4 (en)	2015-09-23	VIDEO SEARCH
EP2929742A4 (en)	2015-12-23	TRACKING DEVICE
GB201218758D0 (en)	2012-12-05	Compounds
GB201217290D0 (en)	2012-11-14	Compounds
GB201210968D0 (en)	2012-08-01	Compounds
GB201200317D0 (en)	2012-02-22	Compounds